Every earnings call for GLAND — management tone, guidance, KPIs and promise tracking, quarter by quarter.
GLAND · 6 transcripts · Healthcare · latest Q4 FY26Gland Pharma Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue 17428 million (+22% YoY); Adjusted EBITDA 5244 million; Adjusted EBITDA Margin 30.0%. Revenue of ₹17,428 million, up 22% YoY.
Read full transcript & analysisRevenue 16954 million (+22% YoY); Adjusted EBITDA 4490 million (+25% YoY); EBITDA Margin 26%. Consolidated revenue reached ₹16,954 million, representing a 22% YoY growth.
Read full transcript & analysisRevenue 14869 million (+6% YoY); EBITDA Margin 21%; PAT 1837 million (+12% YoY). Consolidated Revenue reached ₹14,869 million, representing a 6% YoY growth.
Read full transcript & analysisRevenue 15056 million (+7% YoY); EBITDA 3678 million (+39% YoY); EBITDA Margin 24%. Consolidated Revenue reached ₹15,056 million, representing a 7% YoY growth.
Read full transcript & analysisRevenue ₹1,425 cr; EBITDA Margin 24.0%; PAT ₹186 cr (+3% YoY). Consolidated Revenue for Q4 FY25 stood at ₹1,424.9 crores, showing sequential improvement over Q3.
Read full transcript & analysisRevenue 13841 million INR; EBITDA Margin 26%; PAT 2047 million INR (+7% YoY). Consolidated Revenue stood at ₹1,384.1 crore (INR 13,841 million), with a consolidated EBITDA margin of 26%, up 300 bps YoY.
Read full transcript & analysis